Essex Woodlands Management, Inc. - Q1 2016 holdings

$382 Million is the total value of Essex Woodlands Management, Inc.'s 9 reported holdings in Q1 2016. The portfolio turnover from Q4 2015 to Q1 2016 was 0.0% .

 Value Shares↓ Weighting
ABMD SellABIOMED INC$137,475,000
-29.2%
1,450,000
-32.6%
35.98%
+1.4%
RVNC  REVANCE THERAPEUTICS INC$80,177,000
-48.9%
4,592,0470.0%20.98%
-26.9%
ENTL  ENTELLUS MED INC$69,362,000
+7.9%
3,813,1970.0%18.15%
+54.4%
CORI  CORIUM INTL INC$36,104,000
-52.5%
9,353,3040.0%9.45%
-32.0%
AXGN  AXOGEN INC$26,056,000
+7.2%
4,861,1110.0%6.82%
+53.4%
ELGX  ENDOLOGIX INC$16,776,000
-9.2%
1,257,4680.0%4.39%
+29.9%
MNOV  MEDICINOVA INC$8,591,000
+106.8%
1,170,3700.0%2.25%
+195.8%
ACUR  ACURA PHARMACEUTICALS INC$5,537,000
+13.2%
1,956,3970.0%1.45%
+62.1%
CBIO  CATALYST BIOSCIENCES INC$2,017,000
-46.6%
1,179,3520.0%0.53%
-23.6%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2016-05-12
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
MEDICINOVA INC42Q3 20236.5%
REVANCE THERAPEUTICS INC39Q3 202344.6%
AXOGEN INC26Q4 202143.3%
ENDOLOGIX INC24Q1 201922.5%
ABIOMED INC20Q1 201852.1%
CORIUM INTL INC20Q1 201923.5%
TELA BIO, INC.16Q3 202331.5%
VENUS CONCEPT, INC.16Q3 202321.3%
ACURA PHARMACEUTICALS INC15Q1 20191.4%
CATALYST BIOSCIENCES INC15Q1 20191.0%

View Essex Woodlands Management, Inc.'s complete holdings history.

Latest filings
TypeFiled
13F-HR2024-05-15
13F-HR2024-02-14
13F-HR2023-11-14
13F-HR2023-08-14
13F-HR2023-05-15
13F-HR2023-02-14
13F-HR2022-11-14
13F-HR2022-08-15
13F-HR2022-05-16
13F-HR2022-02-14

View Essex Woodlands Management, Inc.'s complete filings history.

Compare quarters

Export Essex Woodlands Management, Inc.'s holdings